Evidence map›Paper›PMID 39704959›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2025

PSA bounce: understanding temporal fluctuations in prostate cancer after external radiotherapy.

Nicolas Feltes Benitez, Joan Lozano, Carlos G Forero, Montserrat Colomer I Truyols, Saturio Paredes Rubio, Esther Jovell-Fernandez

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nicolas Feltes BenitezRadiation Oncology Department, University Center, Consorci Sanitari de Terrassa, Ctra. De Torrebonica, s/n, 08227, Terrassa, Spain. Nicofeltes_81@hotmail.com.ORCID http://orcid.org/0000-0002-2607-9904
Joan LozanoRadiation Oncology Department, University Center, Consorci Sanitari de Terrassa, Ctra. De Torrebonica, s/n, 08227, Terrassa, Spain.
Carlos G ForeroDepartment of Medicine, School of Medicine and Haalth Sciences, Universitat Internacional de Catalunya, Josep Trueta s/n, 08195, Sant Cugat del Vallès, Spain.
Montserrat Colomer I TruyolsRadiation Oncology Department, Medical Physics Unit, University Center, Consorci Sanitari de Terrassa, Ctra. De Torrebonica, s/n, 08227, Terrassa, Spain.
Saturio Paredes RubioRadiation Oncology Department, University Center, Consorci Sanitari de Terrassa, Ctra. De Torrebonica, s/n, 08227, Terrassa, Spain.
Esther Jovell-FernandezDepartment of Medicine, School of Medicine and Haalth Sciences, Universitat Internacional de Catalunya, Josep Trueta s/n, 08195, Sant Cugat del Vallès, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProstate-specific antigen (PSA) bounce is a transient elevation in PSA levels commonly observed after radiotherapy. This study aims to investigate the characteristics, timing, and clinical implications of PSA bounce (PSA-B) in prostate cancer patients treated with external beam radiotherapy (EBRT), exploring potential causes and its relevance in patient management. MATERIALS AND

methodsBetween 2013 and 2019, 629 patients with localized prostate cancer were treated with EBRT. After excluding patients with fewer than four PSA measurements or follow-up under 3 years (n = 184), 445 patients were analyzed. The median follow-up duration was 5.9 years (36-105 months). PSA-B was defined as a rise of ≥ 0.2 ng/mL above the nadir, followed by a subsequent decline to or below the nadir. PSA relapse was defined according to Phoenix definition.

resultsA total of 64 patients (14.4%) experienced PSA-B at a median of 31 months (6-68 months). Univariable analysis identified age (p < 0.001), risk group (p < 0.001), perineural invasion (p < 0.007), radiotherapy duration (p < 0.001), and the absence of concurrent hormonal therapy (p < 0.001) as independent predictors of PSA-B. Multivariable analysis confirmed age and high-risk group as significant factors. PSA relapse occurred in 10.3% of cases, with only one patient who experienced both PSA-B and relapse.

conclusionsPSA-B is a common phenomenon in localized prostate cancer patients post-EBRT. Factors such as age, risk group, perineural invasion, radiotherapy duration, and hormonal treatment use are associated with PSA-B occurrence. Understanding its mechanisms is crucial for optimizing prostate cancer management.

Indexed as

Prostate-Specific AntigenProstatic NeoplasmsAgedAged, 80 and overFollow-Up StudiesHumansMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTime FactorsProstate-Specific AntigenBiochemical recurrenceExternal radiotherapyHormonal treatmentLHRHaProstate cancer treatment responsePSA bouncePSA dynamicsPSA kineticsTemporary PSA elevation

Identifiers

PMID39704959

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.